| abstract |
The present invention relates to the use of compounds and compositions of compounds having D4nand/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of thenunderlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability -nhypersensitivity - hyperaesthesia - dissociative phenomena -...). The invention also relates tonmethods comprising administering to a patient diagnosed as having a neuropsychiatric disorder anpharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic orninverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic orninverse agonistic, and/or (iii) any known medicinal compound and compositions of saidncompounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonisticneffects may reside within the same chemical or biological compound or in two different chemicalnand/or biological compounds. |